Compositions comprising cromoglicic acid for the treatment of dermatitis

A composition, dermatitis technology, applied in the direction of drug combination, skin care preparations, skin diseases, etc., can solve problems such as skin redness, drug resistance, hirsutism, and stretch marks

Inactive Publication Date: 2019-05-03
DIATER LAB DE DIAGNOSTICO Y APLICACIONES TERAPEUTICAS +1
View PDF10 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, despite their proven clinical efficacy, steroid-based formulations (eg, topical corticosteroid formulations) cause many side effects, such as excessive skin thinning, atrophy, so-called "moon face" caused by facial fat deposits, skin Redness, hirsutism and stretch marks etc.
In addition, when patients use steroids for a long period of time, their bodies often develop resistance to these drugs, and dermatitis symptoms may even recur in a more aggressive form

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions comprising cromoglicic acid for the treatment of dermatitis
  • Compositions comprising cromoglicic acid for the treatment of dermatitis
  • Compositions comprising cromoglicic acid for the treatment of dermatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0197] Embodiment 1: Preparation of 5% disodium cromolyn (5% DSCG) composition

[0198] The indicated percentages correspond to the weight percentages of each ingredient in the final resulting composition.

[0199] In a reactor equipped with pre-sterilized stirring equipment, add water (q.s.f.), disodium EDTA (0.2%), propylene glycol (5%), glycerol (3%) and D-panthenol (2%), which All were mixed and heated at 75°C to 80°C. In a separate regulated vessel, add Steareth-2 (3.5%), Stearyl Alcohol (3.5%), Steareth-21 (3%), Ceteareth-2 Hexanoate (5.7%), Paraffin Oil (3%), Beeswax (0.5%), Dimethicone (0.8%), Phenoxyethanol (0.67%), Stearyl Dimethicone alkanes (0.5%), coco-glycerides (0.5%), isopropyl myristate (0.3%), stearic acid (0.2%) and ethylhexylglycerin (0.075%), all of them are at 75℃~ Mix and heat at 80°C. An emulsion is then prepared from the lipophilic substance and the hydrophilic component with appropriate agitation. Finally, the resulting emulsion was cooled to 4...

Embodiment 2

[0203] Example 2: In vivo studies for the treatment of dermatitis

[0204] The following formulations were tested in a mouse model of dermatitis:

[0205] rat group

The formulation administered

C

none

DC

none

D

5%DSCG

D

2%DSCG

D

DSCG-free

D

2%DSCG (no CL / P)

[0206] in,

[0207] C = control (mice without dermatitis);

[0208] DC = dermatitis control (untreated sensitized mice);

[0209] D = dermatitis (treated sensitized mice).

[0210] The 5% DSCG formulation is the composition prepared according to Example 1.

[0211] The 2% DSCG preparation is a composition prepared according to the preparation method of Example 1, but disodium cromoglycate is added in an amount of only 2wt% relative to the total weight of the composition.

[0212] The DSCG-free preparation is a comparative composition prepared according to the preparation method of Example 1, but the step of adding disodium cromolyn is om...

Embodiment 3

[0222] Example 3: In Vivo Study II for Treatment of Dermatitis

[0223] Animal Models of Dermatitis

[0224] The following sensitization protocol was followed to induce atopic dermatitis in mice. 2,4-Dinitrofluorobenzene (DNFB) was applied to the outer surfaces of both ears of BALB / c strain mice. DNFB administration was stopped when the ear thickness reached 0.55 mm.

[0225] treat

[0226] A formulation of 5% DSCG and 2% DSCG (cream) was started once the administration of DNFB was discontinued. Two groups of mice were used as controls: the first group "C" was neither sensitized nor treated with any formulation, the second group "CD" was used as a dermatitis control which was sensitized but not treated with the formulation.

[0227] The tested preparations (5% DSCG, 2% DSCG) were administered to two groups of mice for 9 days, and the ears were collected.

[0228] All groups of mice consisted of 4 mice (8 ears).

[0229] result

[0230] As expected, no significant chan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
heightaaaaaaaaaa
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

The present invention relates to a combination comprising cromoglicic acid or derivatives thereof and to dermatological compositions comprising said composition. The invention also relates to the useof said combination or composition for the treatment of dermatitis.

Description

technical field [0001] The present invention relates to the dermatological use of novel compositions comprising cromolyn or derivatives thereof. Background technique [0002] Dermatitis is an acute or chronic inflammatory response of the skin, which can be marked by varying degrees of severity. Dermatitis is a disease associated with constitutional factors (such as higher immune susceptibility and genetic alterations) and multiple exposures that induce or contribute to the maintenance and exacerbation of symptoms. [0003] In general, at the onset of dermatitis, edematous erythema is observed, followed by erythematous lesions with papules and serous papules, followed by the formation of vesicles, pustules, erosions, crusts, and desquamation. In cases where the dermatitis is acute, these states can be restored over time in a natural way. However, the entire process is usually recurrent. When dermatitis becomes chronic, skin thickening, lichenification, and hyperpigmentatio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K31/164A61K36/47C07D311/24A61K8/49A61P17/00A61P17/06A61Q19/00
CPCA61K8/49A61Q19/00A61K31/164A61K36/47C07D311/24A61P17/06A61P17/00A61K31/352A61P17/04A61K8/9789A61K8/498A61K9/0014A61K9/06A61K9/107A61K45/06A61K47/10
Inventor 里卡多·帕拉西奥斯·佩莱斯贾维尔·阿尔科韦尔·迪亚兹大卫·罗德里格斯·吉尔费尔南多·皮内达·德·拉·洛萨康塞普西翁·蒂安娜·费雷尔劳拉·费尔南德斯·洛伦扎纳乔瑟·安吉尔·桑切斯·加西亚玛尔塔·维卡里奥·德·拉·托雷
Owner DIATER LAB DE DIAGNOSTICO Y APLICACIONES TERAPEUTICAS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap